Abstract: A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): wherein R1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C1-10 alkyl group, a C1-10 alkoxy group, a C6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C2-10 alkylcarbonyl group, and a C7-18 aralkyl group.

Abstract: A moisturizing base material that contains a lipid peptide compound including at least one of compounds of Formula (1) below and simulated compounds thereof or pharmaceutically usable salts thereof, a surfactant, a specific polyhydric alcohol, a fatty acid, and water. wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; and R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): wherein R1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C1-10 alkyl group, a C1-10 alkoxy group, a C6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C2-10 alkylcarbonyl group, and a C7-18 aralkyl group.

Abstract: A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: A moisturizing base material that contains a lipid peptide compound including at least one of compounds of Formula (1) below and simulated compounds thereof or pharmaceutically usable salts thereof, a surfactant, a specific polyhydric alcohol, a fatty acid, and water. (wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; and R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Abstract: It is an object of the present invention to provide a cosmetic or external skin preparation that has an improved feel in use, e.g., excellent stretching on the skin surface, excellent permeation into the skin, and no stickiness, or crinkles. A cosmetic or an external skin preparation, and a medical instrument, comprising at least one lipid peptide-based gelator that contains a low-molecular lipid peptide of Formula (1): (where R1 to R3 are independently an organic group) or a pharmaceutically usable salt thereof.

Abstract: There is provided a gel sheet that has high biocompatibility and safety, can contain both a hydrophilic medicinal agent and a hydrophobic medicinal agent, and provides an excellent feel in use during the application onto human skin or others. A gel sheet including: a lipid peptide gelator including a low molecular weight lipid peptide having a molecular weight of 1,000 or less or a pharmaceutically usable salt of the lipid peptide; and a polymeric compound, wherein the polymeric compound is included in an amount of more than 1% (w/w) and less than 50% (w/w) with respect to the total mass of the gel sheet.

Abstract: There is provided a lithium-air secondary cell having an air electrode, a negative electrode containing metal lithium or a lithium-containing material and a gel-form solid electrolyte, wherein the gel-form solid electrolyte contains a solid electrolyte salt, a solvent, and a specific lipid peptide-type gelator composed.

Abstract: A spray base material containing an aqueous medium that is gelled by a low-molecular gelator in the medium, wherein the low-molecular gelator includes one or more compounds selected from low-molecular compounds capable of gelling the aqueous medium via self-assembly.

Abstract: There is provided a gelator that is capable of forming a gel by an extremely small amount of addition in a wide pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility, and biodegradability. A gelator comprising: a lipid peptide of Formula (1) wherein R1 is a C9-23 aliphatic group, R2 is a hydrogen atom or a C1-4 alkyl group optionally having a C1-2 branched chain, R3 is a —(CH2)n—X group, n is a number from 1 to 4, and X is an amino group, a guanidino group, a —CONH2 group, or a 5-membered ring optionally having 1 to 3 nitrogen atoms, a 6-membered ring optionally having 1 to 3 nitrogen atoms, or a fused heterocycle including a 5-membered ring and a 6-membered ring that optionally has 1 to 3 nitrogen atoms); or a pharmaceutically usable salt of the lipid peptide.

Abstract: A gelator that includes a lipid peptide of Formula (1) wherein R1 is a C9-23 aliphatic group, R2 is a hydrogen atom or a C1-4 alkyl group optionally having a C1-2 branched chain, R3 is a —(CH2)n—X group, n is a number from 1 to 4, and X is an amino group, a guanidino group, a —CONH2 group, or a 5-membered ring optionally having 1 to 3 nitrogen atoms, a 6-membered ring optionally having 1 to 3 nitrogen atoms, or a fused heterocycle including a 5-membered ring and a 6-membered ring that optionally has 1 to 3 nitrogen atoms; or a pharmaceutically usable salt of the lipid peptide.

Abstract: It is an object of the present invention to provide a cosmetic or external skin preparation that has an improved feel in use, e.g., excellent stretching on the skin surface, excellent permeation into the skin, and no stickiness, or crinkles. A cosmetic or an external skin preparation, and a medical instrument, comprising at least one lipid peptide-based gelator that contains a low-molecular lipid peptide of Formula (1): (where R1 to R3 are independently an organic group) or a pharmaceutically usable salt thereof.

Abstract: There is provided a lipid peptide that is capable of forming a hydrogel with an extremely small amount thereof over a liquid property range from acidic to alkaline, and a hydrogel having high environmental suitability, biocompatibility and biodegradability. A lipid peptide represented by Formula (1): (where R1 represents an aliphatic group having 9 to 23 carbon atoms; R2, R3, R4 and R5 independently represent a hydrogen atom, an alkyl group having 1 to 7 carbon atom(s) which optionally has a branched chain having 1 to 3 carbon atom(s), a phenylmethyl group, a phenylethyl group or a —(CH2)n—X group, and at least one of R2, R3, R4 and R5 represents a —(CH2)n—X group; n represents the number of 1 to 4; X represents an amino group, a guanidine group, a —CONH2 group or a 5-membered ring, a 6-membered ring or a fused heterocyclic ring composed of a 5-membered ring and a 6-membered ring which optionally have 1 to 3 nitrogen atom(s); and in represents 1 or 2), and a hydrogel comprising the lipid peptide.

Abstract: There is provided a lithium-air secondary cell having an air electrode, a negative electrode containing metal lithium or a lithium-containing material and a gel-form solid electrolyte, wherein the gel-form solid electrolyte contains a solid electrolyte salt, a solvent, and a specific lipid peptide-type gelator composed.

Abstract: There is provided a lipid peptide that is capable of forming a hydrogel with an extremely small amount thereof over a liquid property range from acidic to alkaline, and a hydrogel having high environmental suitability, biocompatibility and biodegradability. A lipid peptide represented by Formula (1): where R1 represents an aliphatic group having 9 to 23 carbon atoms; R2, R3, R4 and R5 independently represent a hydrogen atom, an alkyl group having 1 to 7 carbon atom(s) which optionally has a branched chain having 1 to 3 carbon atom(s), a phenylmethyl group, a phenylethyl group or a —(CH2)n—X group, and at least one of R2, R3, R4 and R5 represents a —(CH2)n—X group; n represents the number of 1 to 4; X represents a guanidino group, a —CONH2 group or a 5-membered ring, a 6-membered ring or a fused heterocyclic ring composed of a 5-membered ring and a 6-membered ring which optionally have 1 to 3 nitrogen atom(s); and m represents 1 or 2, and a hydrogel comprising the lipid peptide.

Abstract: A hydrogel that includes an aqueous solution or an alcohol aqueous solution, and a hydrogelator containing a lipid peptide represented by Formula (1), or a pharmaceutically usable salt thereof. In Formula (1), R1 represents an aliphatic group having 9 to 21 carbon atoms; R2, R3, and R4 independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms that optionally has a branched chain having 1 or 2 carbon atoms, a phenylmethyl group, or a —(CH2)n—X group, and at least one of R2, R3, and R4 represents a —(CH2)n—X group; n represents an integer from 1 to 4; and X represents an amino group, a guanidino group, a —CONH2 group, or a 5-membered ring, a 6-membered ring or a fused heterocyclic ring composed of a 5-membered ring and a 6-membered ring that optionally has 1 to 3 nitrogen atoms.